Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
11.00
+0.12 (1.10%)
Jan 17, 2025, 4:00 PM EST - Market closed
Upstream Bio Revenue
Upstream Bio had revenue of $607.00K in the quarter ending September 30, 2024, a decrease of -7.26%. This brings the company's revenue in the last twelve months to $2.21M. In the year 2023, Upstream Bio had annual revenue of $2.38M with 96.37% growth.
Revenue (ttm)
$2.21M
Revenue Growth
+96.37%
P/S Ratio
14.28
Revenue / Employee
$58,079
Employees
38
Market Cap
589.56M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
Dec 31, 2022 | 1.21M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUPB News
- 5 weeks ago - Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation - Seeking Alpha
- 5 weeks ago - Upstream Bio Announces Addition to Russell 2000® Index - GlobeNewsWire
- 2 months ago - Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say - Benzinga
- 3 months ago - Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut - Reuters
- 3 months ago - Upstream Bio raises $255 mln in US IPO - Reuters
- 3 months ago - Upstream Bio Announces Pricing of Upsized Initial Public Offering - GlobeNewsWire
- 4 months ago - Respiratory disorder biotech Upstream Bio files for a $100 million IPO - Renaissance Capital